ReviewCancers2022
Anaplastic Thyroid Carcinoma: An Update.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.
- Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Latin American Thyroid Society expert panel consensus on anaplastic thyroid cancer.Archives of endocrinology and metabolism · 2026Article
- Single-Cell Transcriptome of Anaplastic Thyroid Cancer Reveals Immunosuppressive Tumor Microenvironment Remodeling.Cancer medicine · 2026Article
- Single-cell RNA sequencing: a powerful tool to study heterogeneity in papillary and anaplastic thyroid carcinoma.European thyroid journal · 2026Review
- Neoadjuvant Therapies for Thyroid Cancer: A Scoping Review.The Laryngoscope · 2026Article
- Mechanisms of Yiguanjian Decoction against Thyroid Cancer: A Network-Based Pharmacological Investigation.Chinese journal of integrative medicine · 2026Article
- Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers.European thyroid journal · 2026Observational
- Anaplastic thyroid carcinoma with osteoclast-like giant cells: a case report and a study of a potential therapeutic approach.Medical molecular morphology · 2026Article
- Cancer Stemness and Dedifferentiation in Anaplastic Thyroid Carcinoma: Insights into a Multigenic, Microenvironmental Network and the Role of CD44.Biomedicines · 2026Review
- Anaplastic Thyroid Carcinoma and High-Grade Tall Cell Papillary Thyroid Carcinoma: Case Report of a Rare Association.Reports (MDPI) · 2026Article
- Article
- State of the Art on Thyroid Cancer Biology and Oncology.Biomedicines · 2026Review
- DNA Damage and Repair in Thyroid Physiology and Disease.Endocrine reviews · 2026Review
- The effect of timing of post-operative radiation on outcomes in anaplastic thyroid cancer.Radiation oncology (London, England) · 2026Article
- Lipid Metabolism-Related Genes Define Prognosis and Therapeutic Targets in Thyroid Cancer.International journal of genomics · 2026Article
- Spatial-temporal epidemiological characteristics of thyroid cancer mortality in China cancer registration areas: analysis based on multiple models.Frontiers in oncology · 2026Article
- Isobavachalcone induces concurrent apoptosis and pyroptosis in anaplastic thyroid cancer cells by modulating the caspase-mediated cleavage of PARP and GSDME.American journal of cancer research · 2026Article
- KIF23 Overexpression Promotes Cell Viability, Migration, and Invasion via the Wnt/β-Catenin Signaling Pathway in Anaplastic Thyroid Carcinoma.International journal of endocrinology · 2026Article
- From MAiD Referral to Targeted Therapy Success: A Case ofReports (MDPI) · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic thyroid carcinoma (ATC) is a rare and undifferentiated form of thyroid cancer. Its prognosis is poor: the median overall survival (OS) of patients varies from 4 to 10 months after diagnosis. However, a doubling of the OS time may be possible owing to a more systematic use of molecular tests for targeted therapies and integration of fast-track dedicated care pathways for these patients in tertiary centers. The diagnostic confirmation, if needed, requires an urgent biopsy reread by an expert pathologist with additional immunohistochemical and molecular analyses. Therapeutic management, defined in multidisciplinary meetings, respecting the patient's choice, must start within days following diagnosis. For localized disease diagnosed after primary surgical treatment, adjuvant chemo-radiotherapy is recommended. In the event of locally advanced or metastatic disease, the prognosis is very poor. Treatment should then involve chemotherapy or targeted therapy and decompressive cervical radiotherapy. Here we will review current knowledge on ATC and provide perspectives to improve the management of this deadly disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.